Cyclerion Revenue and Competitors
Estimated Revenue & Valuation
- Cyclerion's estimated annual revenue is currently $3.5M per year.
- Cyclerion's estimated revenue per employee is $196,667
- Cyclerion's current valuation is $60.6M. (January 2022)
Employee Data
- Cyclerion has 18 Employees.
- Cyclerion grew their employee count by -40% last year.
Cyclerion's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Co-Founder and CEO | Reveal Email/Phone |
2 | CEO | Reveal Email/Phone |
3 | Head Biostatistics | Reveal Email/Phone |
4 | Associate Director, Procure to Pay | Reveal Email/Phone |
5 | Sr. Director, Quality, Regulatory, and Safety | Reveal Email/Phone |
6 | Senior Director, Early Development and Clinical Pharmacology | Reveal Email/Phone |
7 | Sr. Director, Corporate Controller | Reveal Email/Phone |
8 | Associate Director, Head DMPK and Toxicology | Reveal Email/Phone |
9 | Director, Analytical CMC and Pharmaceutical Development | Reveal Email/Phone |
10 | Director, Finance, IT and HR Operations | Reveal Email/Phone |
Cyclerion Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5.2M | 67 | -45% | $107.3M | N/A |
#2 | $0.3M | 2 | 0% | N/A | N/A |
#3 | $5.1M | 33 | 6% | N/A | N/A |
#4 | $11.9M | 77 | -37% | $312.8M | N/A |
#5 | $0.9M | 6 | 0% | N/A | N/A |
#6 | $235M | 300 | -5% | $340.9M | N/A |
#7 | $45.9M | 237 | -7% | $7.6M | N/A |
#8 | $3.9M | 50 | 35% | N/A | N/A |
#9 | $5.4M | 35 | 3% | N/A | N/A |
#10 | $1.6M | 10 | 0% | N/A | N/A |
What Is Cyclerion?
Cyclerion Therapeutics is a clinical-stage biopharmaceutical company harnessing the power of sGC pharmacology to discover, develop and commercialize breakthrough treatments for serious and orphan diseases. Cyclerion plans to advance its portfolio of five differentiated sGC stimulator programs with distinct pharmacologic and biodistribution properties that are uniquely designed to target tissues of greatest relevance to the diseases they are intended to treat. These programs, each of which have important milestones in 2019, include olinciguat in Phase 2 development for sickle cell disease, praliciguat in Phase 2 trials for heart failure with preserved ejection fraction (HFpEF) and for diabetic nephropathy, IW-6463 in Phase 1 development for serious and orphan central nervous system diseases, and two late-stage discovery programs targeting serious liver and lung diseases, respectively.
keywords:N/A
N/A
Total Funding
18
Number of Employees
$3.5M
Revenue (est)
-40%
Employee Growth %
$60.6M
Valuation
N/A
Accelerator
Cyclerion News
Cyclerion Therapeutics (NASDAQ:CYCN) Lowered to Sell at Zacks Investment Research. Posted by admin on Apr 12th, 2022.
24, 2022 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company on a mission to develop...
Collaboration to identify patient-selection biomarkers for Cyclerion's investigational therapeutics in neurological and neuropsychiatric...
Other Companies in Cambridge
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $14.1M | 18 | -10% | $161M |
#2 | $3.5M | 18 | N/A | N/A |
#3 | $1.6M | 18 | N/A | N/A |
#4 | $2.5M | 18 | -14% | N/A |
#5 | N/A | 18 | N/A | N/A |